Table 3. Univariable analysis for the effect of time to local recurrence on overall survival after locoregional recurrence.

Variable	Univariable analysis
	HR	95%CI	P
Age
(<65 vs ≥65)	1.075	0.628-1.840	0.792
Gender
(Male vs Female)	0.633	0.364-1.102	0.106
T stage
(T1-2 vs T3-4)	0.876	0.445-1.726	0.703
N stage
(N0-1 vs N2-3)	1.238	0.693-2.211	0.472
Diameter of recurrent lesion
(<2 vs ≥2)	0.966	0.585-1.597	0.894
Site of recurrence
Anastomotic recurrence vs	0.817	0.476-1.402	0.462
Local lymph node recurrence
Time between gastrectomy And recurrence
(<12m vs ≥12m)	0.442	0.264-0.741	0.002
Palliative chemotherapy
(NO vs YES)	0.886	0.540-1.455	0.633
Radiosensitizing Chemotherapy
(NO vs YES)	0.799	0.470-1.360	0.409
Response
(CR+PR vs SD+PD)	1.610	0.923-2.807	0.093
Serum CA 72-4
(≤6.9U/mL vs >6.9U/mL)	1.165	0.601-2.259	0.651
Serum AFP
(≤25μg/L vs >25μg/L)	1.937	0.687-5.458	0.211
Serum CEA
(≤5.9μg/L vs >5.9μg/L)	0.987	0.551-1.754	0.953
Serum CA199
(≤37U/mL vs >37U/mL)	0.959	0.475-1.306	0.876